KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.

Øivind Torkildsen, Hilde Kjelgaard Brustad, Einar August Høgestøl, Karl Bjørnar Alstadhaug, Alok Bhan, Heidi Øyen Flemmen, Andrea Habbestad, Rune A A Høglund, Marissa LeBlanc, Peter Lopen, Åslaug Rudjord Lorentzen, Åse Hagen Morsund, Andreas Lossius, Rigmor Lundby, Gro O Nygaard, Brit Ellen Rød, Cecilia Smith Simonsen, Linn Steffensen, Hilde Torgauten, Fredrik Piehl, Stig Wergeland, Kjell-Morten Myhr, OVERLORD-MS Investigators

N Engl J Med 395(1) 44-53

PMID42384870
PMCID-
DOI10.1056/NEJMoa2600993
发表日期2026-07-01
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Anti-CD20 monoclonal antibodies are effective for relapsing multiple sclerosis. However, data from head-to-head trials are lacking. METHODS: In this phase 3, multicenter, double-blind, noninferiority trial, we randomly assigned adults with newly diagnosed relapsing multiple sclerosis and recent disease activity in a 3:2 ratio to receive rituximab or ocrelizumab every 6 months for 24 months. The primary end point was the absence of new or enlarging lesions on T2-weighted magnetic resonance imaging (MRI) from month 6 to month 24. Noninferiority was defined as a lower limit of the 95% confidence interval for the risk difference (rituximab minus ocrelizumab) of greater than or equal to -10 percentage points. Secondary end points included efficacy and safety. RESULTS: A total of 218 participants underwent randomization; 216 received treatment (132 assigned to the rituximab group and 84 assigned to the ocrelizumab group). Between months 6 and 24, the estimated probability of having no new or enlarging lesions detected on T2-weighted MRI was 92.2% with rituximab and 94.8% with ocrelizumab, corresponding to a risk difference of -2.6 percentage points (95% confidence interval, -9.4 to 4.3), which met the prespecified noninferiority criterion. Relapse rates, disability outcomes, and cognitive-performance profiles appeared to be similar in the two groups. Infections were more common in the rituximab group than in the ocrelizumab group (in 82% vs. 69% of participants), although the percentage of participants with serious adverse events was similar in the two groups (8% and 7%, respectively). CONCLUSIONS: In participants with newly diagnosed relapsing multiple sclerosis and recent disease activity, rituximab was noninferior to ocrelizumab in suppressing disease activity as detected by MRI from 6 to 24 months, with a similar incidence of serious adverse events. (Funded by the Research Council of Norway and others; OVERLORD-MS ClinicalTrials.gov number, NCT04578639; EudraCT number, 2020-001205-23; EU Clinical Trials Register number, 2024-510716-71-00.).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。